Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model
2008

Study of Humanized CYP2C18&19 Mice

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): Löfgren Susanne, Ekman Stina, Terelius Ylva, Fransson-Steen Ronny

Primary Institution: AstraZeneca R&D Södertälje

Hypothesis

The study aims to characterize a gene-addition transgenic mouse model containing human CYP2C18 and CYP2C19 genes.

Conclusion

Despite some observed alterations in organ weights and clinical pathology parameters, the transgenic mice were considered viable and healthy.

Supporting Evidence

  • Transgenic mice showed lower brain and adrenal gland weights compared to wild-type.
  • Male tg-CYP2C18&19 mice had increased blood glucose levels.
  • Female tg-CYP2C18&19 mice had decreased blood triglyceride levels.

Takeaway

Scientists created special mice with human genes to see how they affect health, and found that the mice were mostly healthy even with some changes.

Methodology

The study compared hemizygous tg-CYP2C18&19 mice with wild-type littermates, observing clinical status, pathology, and conducting blood tests.

Potential Biases

Potential bias in the interpretation of the health status of the transgenic mice due to the limited sample size.

Limitations

The study did not explore long-term effects or the full range of metabolic implications of the gene insertions.

Participant Demographics

Mice were hemizygous tg-CYP2C18&19 and wild-type littermates, aged approximately 11 weeks.

Statistical Information

P-Value

p ≤ 0.001

Statistical Significance

p ≤ 0.001

Digital Object Identifier (DOI)

10.1186/1751-0147-50-47

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication